StemCell Therapy

NEW YORK, Jan. 30, 2012 /PRNewswire/ -- Reportlinker.com
announces that a new market research report is available in its
catalogue:

Biobanking for Medicine: Technology and Market
2012-2022

http://www.reportlinker.com/p0765582/Biobanking-for-Medicine-Technology-and-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

Report Details

What does the future hold for biobanks? Visiongain's report
shows you potential revenues and trends to 2022. Find data,
forecasts and discussions for biobanking in medicine.

Discover sales predictions at overall market, submarket and
national levels to 2022. Our study gives you business research,
analysis and opinion for applications in medical research,
pharmaceuticals and diagnostics. 

How will the biobanking industry perform? Receive forecasts for
human tissue banking, stem cell banking, private cord banking,
other services (e.g., DNA and RNA storage), commercial
biobanks, academic collections and other operations. You find
revenues and discussions.

R&D applications are multiplying and widening. Assess
contributions of biobanks in understanding disease, drug
discovery, drug development and biomarkers. This decade will
result in technological and organisational progress, public and
private, benefiting healthcare. 

Our report discusses Cryo-Cell International, Cord Blood
America, Tissue Solutions, Asterand,
ViaCord, LifebankUSA, China Cord Blood and other
organisations. See activities and outlooks. 

Biobanks and biorepositories will become more important to
medical R&D and human healthcare. Biological science and
technology stand to benefit. Discover the prospects. 

Visiongain's study provides data, analysis and opinion aiming
to help your research, calculations, meetings and
presentations. You can find answers now in our work.

Revenue forecasts, market shares, developmental trends,
discussions and interviews

In the report you find revenue forecasting, growth rates,
market shares, qualitative analyses (incl. SWOT and STEP), news
and views. You receive 72 tables and charts and six research
interviews.

Advantages of Biobanking for Medicine: Technology and
Market 2012-2022 for your work

In particular, this study gives you the following knowledge and
benefits:• Find revenue predictions to 2022 for the overall
world market and submarkets, seeing growth trends• Assess
companies in medical biobanking, discovering activities and
outlooks• See revenue forecasts to 2022 in leading countries
for human tissue banking -
US, Japan, Germany,France, UK, Spain, Italy, China and India•
Review developmental trends for biobanks - technologies and
services• Investigate competition and opportunities influencing
commercial results• Find out what will stimulate and restrain
that industry and market• View expert opinions from our survey
of that biotechnology sector.

There, you receive a distinctive mix of quantitative and
qualitative work with independent predictions. We analyse
developments and prospects, helping you to stay ahead.

Gain business research, data and analysis for medical
biobanking Our study is for everybody needing industry
and market analyses for medical biobanks. Find data, trends and
answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal
GovernmentCCR Ref number: KD4R6 

Table of Contents1. Executive Summary

1.1 Summary Points of this Report

1.2 Aims, Scope and Format of the Report

1.2.1 Speculative Aspects of Assessing the Biobanking Market

1.2.2 Chapter Outlines

1.3 Research and Analysis Methods

1.3.1 Human Tissue Banking Market

1.3.2 Stem Cell Banking Market

2. Introduction to Biobanking2.1 Biobanking2.1.1 Processes
Involved in Biobanking2.2 Biobanks: A Two-Fold Character2.3 Key
Features2.4 Classification of Biobanks2.4.1 Volunteer
Groups2.4.1.1 Population-Based Biobanks2.4.1.2 Disease-Oriented
Biobanks2.4.2 Ownership or Funding Structure2.5 Guidelines and
Standards2.5.1 Guidelines for Biobanks and Use of Biological
Samples for Research2.5.2 Industry Standards for Biobanks2.5.3
Biobanking Processes Governed by Guidelines2.6 Laws and
Regulations for Biobank-Based Research

3. Biobanking and the Pharmaceutical Industry

3.1 Scientific and Commercial Use of Biobanking in the
Pharmaceutical Industry

3.1.1 Research and Drug Development

3.1.1.1 Understanding Disease Pathways

3.1.1.2 Drug Discovery

3.1.1.3 Biomarker Discovery

3.1.2 Therapeutics

3.1.3 Clinical Trials

3.2 Biobanks Operated by Pharmaceutical Companies

4. Biobanking Associated Market: Systems, Software, Consumables
and Services Associated with Biobanking4.1 Overview4.2
Systems/Technologies4.2.1 Automated Liquid Handling4.2.1.1
Frozen Aliquotting: New Technology in Development4.2.2
Storage4.2.2.1 Ultra-Low Temperature Freezing4.2.2.2
Room-Temperature Storage4.2.3 RFID and Tagging Technologies4.3
Software4.3.1 Laboratory Information Management System
(LIMS)4.3.1.1 LIMS Functions4.4 Consumables4.5 Services

5. The World Medical Biobanking Market to 2022

5.1 Current State of the Biobanking Market

5.2 Geographical Footprint

5.3 Growing Demand for Biobank Resources

5.4 Revenue Forecast for Overall Market

5.4.1 Scope and Limitations

5.4.2 Biobanking Market, 2011-2022

5.4.2.1 Sales Forecasts for Biobanking Market, 2011-2016

5.4.2.2 Sales Forecasts for Biobanking Market, 2017-2022

5.5 Commercial Biobanks: New Resources for Research

6. Human Tissue Banking Market6.1 Revenue Forecast for Overall
Human Tissue Banking Market, 2011-20226.1.1 Revenue Forecast
for Overall Human Tissue Banking Market, 2011-20166.1.2 Revenue
Forecast for Overall Human Tissue Banking Market, 2017-20226.2
Revenue Forecasts for Human Tissue Banking Market by Type of
Biobank, 2011-20226.2.1 Revenue Forecast for Commercial Human
Tissue Banking Market, 2011-20166.2.2 Revenue Forecast for
Commercial Human Tissue Banking Market, 2017-20226.2.3 Revenue
Forecast for Academic & Other Human Tissue Banking Market,
2011-20166.2.4 Revenue Forecast for Academic & Other Human
Tissue Banking Market, 2017-20226.3 Revenue Forecasts for Human
Tissue Banking in Leading National Markets, 2011-20226.4 Some
Commercial Participants in the Human Tissue Banking Market6.4.1
Business Models of Companies in the Biobanking Market6.4.2
Tissue Solutions6.4.2.1 Overview6.4.2.2 Global Presence6.4.2.3
Products and Services6.4.2.3.1 Banked Samples6.4.2.3.2
Prospective Samples6.4.2.3.3 Fresh Samples6.4.2.3.4 Freshly
Isolated and Primary Cells6.4.2.3.5 Services6.4.2.4 Strengths
and Capabilities6.4.2.5 Future Outlook6.4.3 Asterand6.4.3.1
Overview6.4.3.2 Global Presence6.4.3.3 Products and
Services6.4.3.3.1 XpressBANK6.4.3.3.2 ProCURE6.4.3.3.3
PhaseZERO6.4.3.3.4 BioMAP6.4.3.4 Asterand: Raised Barriers for
New Market Entrants?6.4.3.5 Financial Performance6.4.3.6 Future
Outlook

7. Stem Cell Banking

7.1 Overview

7.2 Revenue Forecast for Overall Stem Cell Banking Market,
2011-2022

7.2.1 Revenue Forecast for Stem Cell Banking Market, 2011-2016

7.2.2 Revenue Forecast for Stem Cell Banking Market, 2017-2022

7.3 Stem Cell Banks for Research: High Growth Possible

7.4 Umbilical Cord Blood Banking for Stem Cells

7.4.1 Blood Banks: Private vs. Public

7.4.2 Biological Insurance: Private Blood Banking

7.4.3 Umbilical Cord Banking: The Controversies

7.4.3.1 US Oversight of Cord Blood Stem Cells

7.4.4 Revenue Forecast for Private Cord Blood Banking Market,
2011-2016

7.4.5 Revenue Forecast for Private Cord Blood Banking Market,
2017-2022

7.4.6 Companies in the Field

7.4.6.1 Cord Blood America: Looking Towards the Chinese
Market

7.4.6.2 ViaCord: 145,000 Blood Units in Storage

7.4.6.3 Cryo-Cell International: The First Cord Blood Bank

7.4.6.4 Stem Cell Authority: Exclusive Stem Cells

7.4.6.5 LifebankUSA: Placenta-Cord Banking

7.4.6.6 Biogenea-Cellgenea

7.4.6.7 China Cord Blood Corp

7.4.6.8 Cryo-Save

7.4.6.9 Thermogenesis

7.5 Gene/DNA Banking

8. Industry Trends8.1 Automated Biobanking8.1.1 Increased
Uptake of Laboratory Information Management Systems (LIMS) in
Biobanking8.1.2 Addressing Sample Storage and Tracking
Issues8.2 Green Banking8.3 Creation of National Biobanks8.4
HIPAA Amendments

9. Qualitative Analysis of the Biobanking Sector

9.1 Strengths

9.1.1 Wealth of Information for Genetic Research

9.1.2 Potential to Change Treatments

9.1.3 Many Governments Support Biobanking

9.2 Weaknesses

9.2.1 Quality Concerns for Some Existing Biospecimen
Collections

9.2.2 Lack of Standardisation and Harmonisation of Best
Practices

9.2.3 Limited Sharing and Linkage of Biobanks

9.3 Opportunities

9.3.1 Genome-Wide Association Studies (GWAS)

9.3.2 Personalised Medicine

9.3.3 Pharmacogenomics: Driving the Personalised Medicine
Approach

9.4 Threats

9.4.1 Ethical and Regulatory Issues

9.4.1.1 Limitations of Informed Consent in Biobanking

9.4.1.2 Confidentiality and Security to Prevent Improper Use

9.4.2 Social and Cultural Issues

9.4.3 Ownership Issues

9.4.4 Funding

10. Research Interviews from Our Survey10.1 Dr Morag McFarlane,
Chief Scientific Officer, Tissue Solutions10.1.1 On the Use of
Biobank Samples in the Pharmaceutical Industry 10.1.2 On
Commercial Aspects of Biobanking10.1.3 On the Business of
Tissue Solutions10.1.4 On the Attractiveness of Human Tissue
Banking10.1.5 On the Future of the Biobanking Market10.2 Dr
Angel García Martín, Director, Inbiomed10.2.1 On the Importance
of Biobanking in the Pharmaceutical Industry 10.2.2 On the
Use of Technology in Biobanking 10.2.3 On Increased
Recognition of Biobanking and Harmonisation of
Samples 10.2.4 On the Use of Biobanks by the
Pharmaceutical Industry 10.2.5 On Private Biobanks and
Scale of Operations 10.2.6 On Commercial and Public
Biobanking and Legislation 10.2.7 On the Most Attractive
Segment in Commercial Biobanking10.2.8 On the Future of
Biobanking: Drivers and Challenges10.3 Dr Piet Smet, Director,
Business Development, BioStorage Technologies10.3.1 On Defining
Biorepositories and Biobanks10.3.2 On the Services of
Biostorage10.3.3 On Main Customers for Biostorage10.3.4 On the
Importance of Biorepositories in Research and Industry10.3.5 On
Technology Use in Biobanks10.3.6 On Increased Recognition of
Biobanking and Harmonisation of Samples 10.3.7 On the Use
of Biobanks by the Pharmaceutical Industry 10.3.8 On
Private Biobanks and Scale of Operations 10.3.9 On
Commercial and Public Biobanking and Legislation 10.3.10
On the Most Attractive Segment in Commercial Biobanking10.3.11
On Biobanking in 202010.3.12 On Drivers and Challenges in the
Sector10.4 Dr Tom Hoksbergen, Marketing and Sales,
SampleNavigator Laboratory Automation Systems10.4.1 On the
Services of SampleNavigator10.4.2 On Main Customers for
SampleNavigator10.4.3 On the Importance of Biorepositories in
Research and Industry10.4.4 On Technology Use in Biobanks10.4.5
On Increased Recognition of Biobanking and Harmonisation of
Samples 10.4.6 On the Use of Biobanks by the
Pharmaceutical Industry 10.4.7 On Commercial
Biorepositories/Banks and Scale of Operations 10.4.8 On
Commercial and Public Biobanking10.4.9 On the Most Attractive
Segment in Commercial Biobanking10.4.10 On Biobanking in
202010.4.11 On Drivers and Challenges in the Sector10.5 Mr Rob
Fannon, Clinical Operations Manager, BioServe10.5.1 On the
Services of BioServe10.5.2 On Main Customers for BioServe10.5.3
On the Importance of Biorepositories in Research and
Industry10.5.4 On Technology Use in Biobanks10.5.5 On Increased
Recognition of Biobanking and Harmonisation of
Samples 10.5.6 On the Use of Biobanks by the
Pharmaceutical Industry 10.5.7 On Commercial
Biorepositories/Banks and Scale of Operations 10.5.8 On
Commercial and Public Biobanking10.5.9 On the Most Attractive
Segment in Commercial Biobanking10.5.10 On Biobanking in
202010.5.11 On Drivers and Challenges in the Sector10.6 Dr
Frans A.L. van der Horst, Chairman, Dutch Collaborative
Biobank10.6.1 On Importance of Biorepositories in Research and
Industry10.6.2 On Increased Recognition of Biobanking and
Harmonisation of Samples 10.6.3 On the Services of Dutch
Collaborative Biobank10.6.4 On Commercial Drivers for
Bio-Repositories/Biobanking Market10.6.5 On Commercial and
Public Biobanking10.6.6 On Sustaining/Recovering Costs10.6.7 On
the Most Attractive Segment in Commercial Biobanking10.6.8 On
Ethical, Legal and Social Issues in Biorepositories/Biobanks

11. Conclusions

11.1 Biobanking for Research and Therapeutics

11.2 Biobanking: The Future for Drug Discovery and Personalised
Medicine

11.3 Commercial Drivers of the Biobanking Market

11.4 The Sector Has Marked Challenges, but Many Opportunities
for Growth

List of TablesTable 2.1 Prominent Population-Based
Biobanks, 2011

Table 2.2 Prominent Disease-Oriented Biobanks, 2011

Table 2.3 Some Guidelines and Recommendations for Biobanks,
2011

Table 2.4 Laws and Regulations for Biobank-Based Research,
Consent Requirements, and Privacy/ Data Protection, 2011

Table 3.1 Some Pharmaceutical and Biotechnology Companies with
In-House Biobanks, 2011

Table 4.1 Prominent Companies in the Automated Liquid Handling
Market, 2011

Table 4.2 Prominent Companies in Ultra-Low Temperature Freezer
Market, 2011

Table 4.3 Prominent LIMS Vendors, 2011

Table 4.4 Prominent Consumables Suppliers for Biobanking, 2011

Table 4.5 Prominent Biorepository Service Providers, 2011

Table 5.1 Estimated Number of Biobanks in Europe, 2011

Table 5.2 Biobanking Market: Grouped Revenue Forecasts,
2010-2016

Table 5.3 Biobanking Market: Grouped Revenue Forecasts,
2017-2022

Table 6.1 Human Tissue Banking Market: Overall Revenue
Forecast, 2010-2016

Table 6.2 Human Tissue Banking Market: Overall Revenue
Forecast, 2017-2022

Table 6.3 Human Tissue Banking Market: Revenue Forecasts by
Type of Biobank, 2010-2016

Table 6.4 Human Tissue Banking Market: Revenue Forecasts by
Type of Biobank, 2017-2022

Table 6.5 Human Tissue Banking Market: Revenue Forecasts for
Leading National Markets, 2010-2016

Table 6.6 Human Tissue Banking Market: Revenue Forecasts for
Leading National Markets, 2017-2022

Table 6.7 Some Leading Companies in the World Biobanking
Market, 2011

Table 6.8 Asterand: Revenue by Segment, 2009 and 2010

Table 6.9 Asterand: Revenue by Geographical Area, 2010

Table 7.1 Stem Cell Banking Market: Overall Revenue Forecast,
2010-2016

Table 7.2 Stem Cell Banking Market: Overall Revenue Forecast,
2017-2022

Table 7.3 Prominent Stem Cell Banks Serving the Research
Community, 2011

Table 7.4 Costs of Various Private Cord Blood Banks Worldwide,
2011

Table 7.5 Private Cord Blood Banking Market: Revenue Forecast,
2010-2016

Table 7.6 Private Cord Blood Banking Market: Revenue Forecast,
2017-2022

Table 7.7 Cord Blood Banking Market: Drivers and Restraints,
2012-2022

Table 7.8 Some Prominent Companies in the Cord Blood Banking
Market, 2011

Table 7.9 Cryo-Cell International Revenue, 2009-2010

Table 7.10 China Cord Blood Corp Revenue and Subscribers,
2009-2010

Table 7.11 Cryo-Save Revenue and Operating Profit, 2009-2010

Table 7.12 Cryo-Save Revenue by Region, 2010

Table 9.1 SWOT Analysis of the Biobanking Market: Strengths and
Weaknesses, 2012-2022

Table 9.2 SWOT Analysis of the Biobanking Market: Opportunities
and Threats, 2012-2022

Table 9.3 Information for a Biobank Donor, 2011

Table 11.1 Human Tissue Biobanking Market by Country, 2010,
2016, 2019 & 2022

List of FiguresFigure 2.1 Main Processes Involved in
Biobanking, 2011

Figure 2.2 Classification of Biobanks, 2011

Figure 3.1 Biobanking and Pharmaceutical Development, 2011

Figure 4.1 Biobanking, Applications and Users, 2011

Figure 4.2 Functions of LIMS, 2011

Figure 5.1 Overall Biobanking Market: Revenue Forecast,
2010-2016

Figure 5.2 Overall Biobanking Market: Revenue Forecast,
2017-2022

Figure 6.1 Human Tissue Banking Market: Overall Revenue
Forecast, 2010-2016

Figure 6.2 Human Tissue Banking Market: Overall Revenue
Forecast, 2017-2022

Figure 6.3 Human Tissue Banking Market: Forecast by Type of
Biobank, 2010-2016

Figure 6.4 Human Tissue Banking Market: Forecast by Type of
Biobank, 2017-2022

Figure 6.5 Human Tissue Banking Market: Share by Type of
Biobank, 2010

Figure 6.6 Human Tissue Banking Market: Share by Type of
Biobank, 2022

Figure 6.7 World and US Human Tissue Banking Markets: Revenue
Forecasts, 2010-2022

Figure 6.8 Japan, EU 5 and Other Leading Human Tissue
Banking Markets: National Revenue Forecasts, 2010-2022

Figure 6.9 Human Tissue Banking: National Market Shares, 2010

Figure 6.10 Human Tissue Banking: National Market Shares, 2016

Figure 6.11 Human Tissue Banking: National Market Shares, 2019

Figure 6.12 Human Tissue Banking: National Market Shares, 2022

Figure 6.13 Commercial Sourcing of Biological Samples, 2011

Figure 6.14 Commercial Banking of Biological Samples, 2011

Figure 6.15 Asterand: Revenues, 2009 & 2010

Figure 6.16 Asterand: Revenue Shares by Region of Destination,
2010

Figure 6.17 Asterand: Revenue Shares by Region of Origin, 2010

Figure 7.1 Stem Cell Banking Market: Revenue Forecast,
2010-2016

Figure 7.2 Stem Cell Banking Market: Revenue Forecast,
2017-2022

Figure 7.3 Twenty-Year Storage Costs at Various Private Cord
Blood Banks Worldwide, 2011

Figure 7.4 Cord Blood Banking Market: Revenue Forecast,
2010-2016

Figure 7.5 Cord Blood Banking Market: Revenue Forecast,
2017-2022

Figure 7.6 Cryo-Cell International Revenue, 2009-2010

Figure 7.7 China Cord Blood Corp Revenue and Subscribers,
2009-2010

Figure 7.8 Cryo-Save Revenue and Operating Profit, 2009-2010

Figure 7.9 Cryo-Save Revenue Shares by Region, 2010

Figure 11.1 Biobanking Market: World Sales Forecast, 2010,
2012, 2016, 2019 & 2022 

Companies ListedAbcellute

Abgene

Adnexus Therapeutics

AFNOR Groupe

AKH Biobank

AlloSource

American National Bioethics Advisory Commission 

American Type Culture Collection

Amgen

Analytical Biological Services

ARCH Venture Partners

Asterand

AstraZeneca

Australasian Biospecimen Network (ABN)

Autoscribe

AXM Pharma 

Bayer-Schering

Beckman Coulter

Beike Biotechnology 

Biobank Ireland Trust

Biobank Japan

Biobanking and Biomolecular Resources Research Infrastructure
(BBMRI) 

BioFortis

Biogen Idec

Biogenea-CellGenea 

BioLife Solutions

Biomatrica

Biopta

BioRep

BioSeek

BioServe

BioStorage LLC

BioStorage Technologies

BrainNet Europe

Caliper LifeSciences

Canadian Partnership for Tomorrow

CARTaGENE

Cellgene Corporation

Cells4Health

Chemagen

China Cord Blood Corp

Chinese Ministry of Health

CLB/Amsterdam Medical Center

CorCell

Cord Blood America

Cord Blood Registry 

CORD:USE (US Public Cord Blood Bank) 

CordLife

Cordon Vital (CBR) 

Coriell Institute for Medical Research

Council of Europe (CoE)

Covance

Cryo Bio System

Cryo-Cell International

Cryometrix

Cryo-Save

Cureline

Cybrdi

Danubian Biobank Foundation

deCODE Genetics

Department of Health (DoH, UK)

Draper Laboratory

Duke University Medical Center

Dutch Collaborative Biobank

EGeen

Eli Lilly

Eolas Biosciences 

Estonian Genome Project

EuroBioBank

European Commission (EC)

European Health Risk Monitoring (EHRM)

European Medicines Agency (EMA/EMEA)

European Union Group on Ethics (EGE)

Fisher BioServices

Fondazione I.R.C.C.S. Istituto Neurologico C. Besta

Food and Drug Administration (US FDA)

Foundation for the National Institutes of Health 

Fundación Istituto Valenciano de Oncología

Fundeni Clinical Institute

Genentech

Generation Scotland

GeneSaver

GeneSys

Genetic Association Information Network (GAIN)

Genizon Biosciences

Genome Quebec Biobank 

GenomEUtwin

Genomic Studies of Latvian Population

GenVault

German Dementia Competence Network

GlaxoSmithKline (GSK)

H. Lee Moffitt Cancer Center and
Research Institute 

Hamilton

Hopital Necker Paris - Necker DNA Bank

Human Tissue Authority (HTA)

Hungarian Biobank

HUNT, Norway

ILSBio LLC

Inbiobank

Inbiomed

Indivumed

INMEGEN

Institut National de la Santé et de la Recherche Médicale
(INSERM)

Integrated BioBank of Luxembourg

International Agency for Research on Cancer (IARC)

International Air Transport Association (IATA)

International Organization for Standardization (ISO)

International Society for Biological and Environmental
Repositories (ISBER)

International Stem Cell Corporation

Kaiser Permanente

KORA-gen

LabVantage Solutions

LabWare

Leiden University Medical Center

LifebankUSA

LifeGene

LifeStem

Malaysian Cohort Project

Matrical Biosciences

Matrix

Medical Research Council (MRC)

Medical University of Gdansk

Merck & Co.

Merck Sharp & Dohme Limited (MSD)

Merck-Serono

Micronic

Millennium (Takeda Oncology Company)

MVE-Chart

National Cancer Institute (NCI)

National DNA Bank (US)

National Human Genome Research Institute (NHGRI)

National Institute of Environmental Health

National Institutes of Health (NIH)

National Public Health Institute 

National Research Ethics Service (NRES) 

NeoCodex

NeoStem

Neuromuscular Bank of Tissues and DNA Samples

New Brunswick Scientific

NEXUS Biosystems

Northwest Regional Development Agency

Novacare Bio-Logistics

Novartis

NUgene Project

Ocimum Biosolutions

Office of Biorepositories and Biospecimen Research (OBBR)

OnCore UK

Organisation for Economic Co-operation and Development (OECD)

OriGene

Oxagen

Pacific Bio-Material Management

PathServe

Perkin Elmer

Pfizer

Pharmagene Laboratories Trustees Limited

Polaris Ventures 

Pop-Gen (University Hospital Schleswig-Holstein)

PrecisionMed

Prevention Genetics

ProMedDx

Promoting Harmonisation of Epidemiological Biobanks
in Europe (PHOEBE)

ProteoGenex

Public Population Projects in Genomics (P3G Consortium)

Qiagen

RAND Corporation

Regenetech

REMP

Reproductive Genetics Institute (RGI)

Research Centre of Vascular
Diseases, University of Milan

Rhode Island BioBank, Brown University

Roche

RTS Life Science

Saga Investments LLC

SampleNavigator Laboratory Automation Systems

Sanofi

SANYO Biomedical

Scottish Government

Seattle Genetics

Sejtbank (Hungarian Cord Blood Bank) 

SeqWright DNA Technology Services

SeraCare Life Sciences

Singapore Tissue Network

StarLIMS

Steelgate

Stem Cell Authority

Stem Cells for Safer Medicine (SC4SM)

Stem Cells Research Forum of India

Stemride International

Taiwan Biobank

Taizhou Biobank

TAP

Tecan

The Automation Partnership

The Sorenson Molecular Genealogy Foundation (SMGF)

Thermo Fisher Scientific

Thermogenesis

Tissue Bank Cryo Center (Bulgaria)

Tissue Solutions

Titan Pharmaceuticals

TotipotentSC

Trinity Biobank

Tumorothèque Necker-Entants Malades

UK Biobank

UK Stem Cell Bank

UmanGenomics

Umeå University

University Hospital Angers

University Medical Center Gent

University of Massachusetts Stem Cell Bank

University of Tuebingen, Department of Medical
Genetics

US Biomax

Västerbotten County Council

ViaCord

Wellcome Trust

Wellcome Trust Case-Control Consortium (WTCCC)

Western Australian Genome Health Project

Wheaton Science International

Wisconsin International Stem Cell (WISC) Bank

World Health Organization (WHO)

Zhejiang Lukou Biotechnology Co 

To order this report:Blood Supply, Tissue Banking and Transplantation
Industry: Biobanking for Medicine: Technology and Market
2012-2022

More  

Market Research Report

Check our  

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

 

Read more from the original source:
Biobanking for Medicine: Technology and Market 2012-2022

This entry was posted on January 30, 2012 at 9:18 pm and is filed under Cell Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |